Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context
Summary: Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study. Methods: This was an observer-blind, randomised, p...
Saved in:
Similar Items
-
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
by: Eddie Underwood, et al.
Published: (2023) -
Angioedema‐like eyelid edema following the second NVX‐CoV2373 COVID‐19 vaccination
by: Mari Matsumoto, et al.
Published: (2023) -
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines
by: Anthony M. Marchese, et al.
Published: (2023) -
Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
by: Diego Macías Saint-Gerons, et al.
Published: (2023) -
It's Time to Invest in Geriatric Nutrition: A Systematic Review
by: Ruchita Khandre, et al.
Published: (2023)